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Abstract
Purpose. To assess the effectiveness of Ir-192 interstitial brachytherapy as an adjunct to wide local excision as a function-
saving strategy for soft tissue sarcomas.
Subjects and methods. From September 1993 to April 1998, 20 consecutive patients diagnosed with soft tissue sarcomas
were treated with a combination of wide local excision and interstitial brachytherapy. In 16 patients brachytherapy was done
as an intraoperative procedure, while in four, the implant was performed post-operatively under local anesthesia. Eleven of
the 20 patients also received external beam radiotherapy following the implant.
Results. After a mean follow-up of 27 months (4± 54) the local control rate for all 20 patients was 85% (17/20). In the 16
patients who had an intra-operative implant, local control was 94% (15/16). In the four patients who underwent a
post-operative implant, local control was 50% (2/4). Actuarial 5-year survival was 90%. There were three cases (15%) of
severe local complications.
Conclusions. Wide local excision followed by low dose rate intersitital brachytherapy have yielded a 85% local control rate
in 20 patients with soft tissue sarcomas. Local control rates were higher when the implants were done as an intra-operative
procedure than as a post-operative one.
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Introduction
Over the last three decades several strategies have
been used to avoid limb amputation while preserving
local control rates in soft tissue sarcomas of the
extremities. These include wide en bloc resection of
soft parts, also known as compartmental resection,
1± 3
pre- or post-operative external radiation therapy,
4± 6
regional intra-arterial infusion
7 or perfusion
chemotherapy,
8 and brachytherapy
9± 13. Each of these
treatment methods has advantages and limitations.
The role of local brachytherapy as an adjunct to
radical surgery has been clearly established by several
investigators including the pioneer experience of the
group at Memorial Sloan-Kettering.
14± 16
In this paper we describe our experience with low
dose rate interstitial brachytherapy in a series of 20
patients with soft tissue tissue tumors at various
anatomical locations.
Patients and methods
Between September 1993 and March 1998, 20
patients with soft tissue sarcomas were managed with
wide local excision and low dose rate interstitial
brachytherapy as part of their treatment strategy.
Patient characteristics are presented in Table 1.
The selection criteria were that all patients with a
soft tissue tumor who were found eligible for general
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Table 1. Patient characteristics
Total number of patients 20
Mean age (range 53 (12± 90)
Male/female ratio 8/12
Adults (>15 years old) 18
Pediatric (<15 years old) 2
Limbs 13
Trunk 5
Head and neck 2
Histologic types
Malignant ® brous hystiocytoma (MFH) 5
Liposarcoma 1
Leiomyosarcoma 6
Fibrosarcoma 2
Hemangiopericytoma 2
Malignant peripheral nerve sheath 1
Extraskeletal Ewing sarcoma (PNET) 1
Chondroid syringoma 1
Aggressive ® bromatosis 1
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found compliant to undergo LDR brachytherapy
under radiation precaution measures were selected.
All patients received an explanation of the procedures,
and informed consent for surgery and radiotherapy
was obtained.There were eight males and 12 females;
mean age was 53 years (range, 12± 90). In 13 patients
the tumor was located in the limbs (right arm, two
left arm, two; right forearm, one; right gluteal, one;
left gluteal, one; right thigh, two; left thigh, two; left
groin, one; left leg one), while in ® ve it was in the
trunk and in two in the head-and-neck region,
including one patient with a leiomyosarcoma of the
tongue.Two patients were in the pediatric age group.
There were nine patients with stage I tumors
(T1a± 1b, T2a, N0), seven stage II (T2b, N0) and
four stage III patients.
17 The grading system used
was a two-grade system (low grade, G1 and G2, well
and moderately differentiated; and high grade, G3
poorly differentiated and G4, undifferentiated) as
recognized by the AJCC and as incorporated into the
TNM stage grouping.
17 Following this classi® cation
there were four low-grade tumors (desmoid tumor,
mixed liposarcoma, low-grade ® brosarcoma and a
chondroid syringoma of the subcutaneous tissue).
There was one case of extraskeletal Ewing’s sarcoma/
PNET of the anterior abdominal wall.
In 16 patients the brachytherapy was done as an
intra-operative procedure immediately following wide
local excision of the tumor or of the tumor bed after
a marginal resection.These 16 patients were initially
seen in a consultation before surgery/brachytherapy
at a multidisciplinary sarcoma clinic including
surgeons (N.M., M.E.) and radiation oncologists
(E.R., A.K.). In the remaining four patients, brachy-
therapy was done post-operatively in patients previ-
ously resected with inadequate margins. These four
patients were referred to our clinic following a surgical
procedure at another hospital.
Intra-operative brachytherapy procedures
Elective wide excision and intra-operative brachy-
therapy were recommended in all 16 patients seen by
us following a biopsy or marginal excision. Post-
operative brachytherapy was done in the four patients
operated elsewhere and in whom it was felt that an
additional surgical procedure could not be done. In
the initial nine patients of this series, and following
the experience of Harrison et al.
16 and Gerbaulet et
al.,
20 we attempted to give all the radiotherapy dose
with an implant alone. We observed three cases of
severe wound complications following the implant
(see Results) and thus we changed our treatment
policy giving only a third of the radiotherapy dose
with the implant, and the additional two thirds by
external beam techniques.
Under general anesthesia a wide local excision was
performed dissecting through the healthy tissue
surrounding the tumor except in areas where it came
into close proximity with bone or with the neurovas-
cular bundle of the limb. In these areas the tumor
was peeled from these structures and brachytherapy
catheters were placed above these high-risk regions.
Following tumor resection, gloves and instruments
were changed.After the surgeon completed the tumor
resection the tumor bed was marked with metallic
clips for radiological identi® cation. Under direct
visualization a decision was made on the area to be
implanted, attempting to cover the tumor bed with
an additional 2 cm beyond the actual tumor confines.
A series of parallel catheters were percutaneously
inserted into the target area, placed approximately
1 cm apart and secured in proper position using catgut
sutures as required. The entrance and exit points of
the catheters were kept at not less than 1.5 cm from
the surgical wound (Fig. 1). The wound was closed
by approximation of soft tissues and skin over the
catheters, care being taken to leave a drainage tube
and thick viable ¯ aps. Plastic and metallic brachy-
therapy buttons were anchored to the skin with loose
stitches at the entrance and exit sites of the implant.
Five to 7 days after the surgical procedure, a pair of
orthogonal radiographs of the implant, loaded with
dummy metal sources, was obtained for source
localization and computerized treatment planning.
The implant was then loaded with iridium-192
radioactive sources with an activity of 1.8 mCi/seed
(BEST Industries, Inc., Spring® eld, VA) not earlier
than the ® fth post-operative day. The median tumor
bed implant dose was 3300 cGy (1800± 4900)
delivered over 2± 5 days. The dose was prescribed to
an isodose located approximately 0.5 cm from the
plane of the sources. This nominal prescribed dose
represents the minimal dose within the target volume,
the dose between or nearer the sources being
signi® cantly higher.
18 In 11 of 20 patients the
interstitial implant was used to deliver part
(approximately one-third) of the irradiation dose. In
these patients the median implant dose was 2300
cGy (1800± 3000). In nine of 20 patients the implant
was the sole radiotherapy modality. Hence, in this
Fig. 1. Single plane interstitial implant for a sarcoma of the
right leg following wide local excision. Note entrance and exit
sites of catheters far from the surgical wound. Plastic and metal
buttons have been sewn to the skin with loose stitches.
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cGy (4500± 4900). The variations on the prescribed
dose depended on the assessment of clinical variables
such as: anatomical site and proximity to sensitive
structures, prior irradiation, geometric quality of the
implant and potential risk for wound complications.
When the implant plane was relatively close to the
skin or neurovascular bundle, the lower dose (4500
cGy) was prescribed. In one patient with a hemangi-
opericytoma of the left groin resected with a positive
margin, 4900 cGy was prescribed. This patient
developed a local recurrence 3 years following the
implant.The average implant dose rate was 48 cGy/h.
Eleven of 20 patients (55%) also received
supplementary external beam irradiation to a median
dose of 3920 cGy (1620± 4500). No patient received
post-operative adjuvant chemotherapy. In the two
pediatric patients, chemotherapy was given before
the surgical brachytherapy procedure. A 15-year-old
boy with a low-grade ® brosarcoma of the neck
received Cisplatin concomitantly with external irradia-
tion before surgery/brachytherapy. A 12-year-old girl
with a high-grade ® brosarcoma of the left thigh
received three courses of ifosfamide± etoposide±
mesna before surgery without response. In four
patients the brachytherapy implant was performed as
a separate procedure following a surgical resection
with positive or close margins. This was done under
local anesthesia and using brachytherapy needles as
guides for the nylon tubes in the usual manner.
Results
After a mean follow-up of 27 months (4± 54) the
local control rate for all 20 patients was 85% (17/20).
Actuarial 5-year survival was 90%.Two patients died;
one of heart failure and the other of sepsis following
infection of the surgical wound.
Three patients eventually had failure at the implant
site. Local recurrences presented at 2, 3 and 4 years
following brachytherapy. One patient developed lung
metastasis, being locally controlled at the primary
tumor site.
In the 16-patients who had an intra-operative
implant local control was 94% (15/16); in the four
patients who underwent a post-operative implant local
control was 50% (2/4).Table 2 presents local control
rate as a function of various treatment variables.
Complications
All patients developed variable degrees of erythema
of the skin overlying the implant site 7± 10 days
following brachytherapy.This subsequently subsided.
Eleven patients (55%) developed chronic radiation
changes at the implant site (NCI-CTC grade 2± 3
toxicity). This changes consisted of dryness of the
skin, subcutaneous ® brosis and telangiectasia. In
several patients, these chronic radiation changes
coexisted with cosmetic defects due to the surgical
resection of a variable amount of soft tissue. Six of 11
patients with chronic radiation changes received an
implant as the sole modality of radiotherapy, while in
® ve patients the implant (to a lower dose) was followed
by external beam irradiation.
We observed three cases of severe local complica-
tions. An 84-year-old diabetic patient with a large
recurrence of MFH in her right gluteal area developed
a wound infection and died of septic shock 2 months
following surgery and brachytherapy.
A 12-year-old girl with a high-grade ® brosarcoma
of the right thigh which did not respond to induction
Fig. 2. Radiograph of a single plane implant in the left arm
with dummy metal sources for localization and dosimetry.
Table 2. Local control rates according to various clinical
and treatment variables
Variable N
Locally
controlled
Adults 18 15
Children 2 2
Limbs 13 12
Trunk/head and neck 7 5
Intra-operative implant 16 15
Post-operative implant 4 2
Brachytherapy + EBRT 11 11
Brachytherapy alone 9 6
Adequate margins 15 15
Inadequate margins (< 5 mm or positive) 5 3
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subcutaneous necrosis, with subsequent delay in
wound healing and knee contracture, in the months
following treatment. This patient received 4500 cGy
to the 0.5-cm plane with brachytherapy alone. Soft
tissue necrosis was controlled with hyperbaric oxygen
therapy and the knee function impairment required
prolonged rehabilitation.
One patient developed a local abcess which resolved
with incision and drainage.
Discussion
Interstitial brachytherapy with Ir-192 as an adjuvant
to radical surgery has already been shown to provide
good local control rates in soft tissue sarcomas.
9± 16
The use of brachytherapy as an adjuvant to surgery is
based on its theoretical and practical advantages over
external beam irradiation. The brachytherapy
catheters are inserted in the tumor bed under direct
visualization by the surgeon and the oncologist.
Therefore, the high radiation dose is given to a target
volume which encompasses the area with the greatest
risk of containing residual microscopic disease.
Because of the rapid fall-off of the dose with distance,
the surrounding tissues are relatively spared and the
use of low dose rate sources provides for a greater
sparing of normal tissues.
In a prospective randomized trial that included
164 patients, Harrison et al.
16obtained a local control
rate of 82% with complete resection followed by
Ir-192 brachytherapy, compared to 69% with surgery
alone. In this trial the improvement in local control
was limited to patients with high-grade histology, while
patients with low-grade tumors did not bene® t. Adju-
vant brachytherapy improved local control, but did
not have any signi® cant impact on distant metastases
or tumor-related mortality.
The role of radiation therapy in low-grade tumors
has not been clearly elucidated. For relatively small
lesions that have been completely excised with nega-
tive margins, postoperative irradiation is usually not
recommended since a substantial fraction of these
patients are cured by the surgical procedure. In these
lesions radiotherapy is usually reserved for patients
with positive margins, deep lesions that are difficult
to follow or questionable margins in a location in
which a local recurrence would require amputation.
However, histologically low-grade tumors like ® bro-
sarcoma grade I (aggressive ® bromatosis, desmoid,
dermato® brosarcoma protuberans) have a typical 50%
local recurrence rate following adequate surgery
alone.
19
In the present series brachytherapy was used in
three patients with low-grade lesions: one with mixoid
liposarcoma, a low-grade ® brosarcoma of the neck in
a 15-year-old and a case of desmoid tumor (® brosar-
coma grade I) that recurred for the third time. In
these three patients local control was obtained.
The Memorial experience in the early years of
their trial
16 showed more major wound complica-
tions (11 of 23 patients) when the implants were
loaded within the ® rst 5 post-operative days, than
when the loading was done after the ® fth post-
operative day (three of 21 patients). Following these
results we loaded our implants not earlier than the
® fth post-operative day.This timing allows the prolifera-
tive phase of wound healing to proceed without being
impaired by radiation-induced reduction in ® broblast
populations.We observed severe wound complications
in two cases with probable predisposing factors. An
84-year-old patient with diabetes and ischemic heart
disease was treated for a large (63 93 11 cm) recur-
rence of high-grade MFH in her gluteal region. This
patient remained bedridden after the surgery/
brachytherapy procedure. She subsequently developed
wound infection and died of sepsis.
A 12-year-old girl with a high-grade ® brosarcoma
of the thigh had previously received three courses of
ifosfamide± etoposide± mesna combination chemo-
therapy without response. In this patient a wide local
excision of the tumor was followed by full-dose
brachytherapy (4500 cGy) to the tumor bed. The
patient’s age and previous chemotherapy may have
been predisposing factors for the local complication.
In the largest published series of low dose rate brachy-
therapy in children Gerbaulet et al.
20 treated 45
children giving prescribed doses of 6000± 7500 cGy
(Paris system). After a mean follow-up of 5 years,
78% of the patients were alive with no evidence of
disease. A severe complication rate of 18% was
observed in six of 33 evaluable patients. These six
children received doses between 5800 and 7500 cGy
to the prescription isodose, and in these cases,
sequelae can probably be related to the high doses
delivered with the implants. Being essentially a local
modality treatment, brachytherapy success rates
should be assessed in terms of local control. Current
results are showing bene® ts for this radiotherapy
modality in intermediate- and high-grade sarcomas
following wide local excision. However, it is still
unclear whether brachytherapy should be used alone
or in combination with external beam techniques:
and, if brachytherapy can be used alone, what would
be the minimal effective dose to maintain current
local control rates while minimizing wound complica-
tions? We feel that these two questions should be
addressed and answered in future clinical trials.
In addition, there is an ongoing debate about the
impact of local control on the development of distant
metastases and disease-speci® c survival in patients
with soft tissue sarcomas.
The importance of obtaining negative margins in
the resection of soft tissue tumors is well established.
It is noteworthy that our three patients who failed
locally had been resected with inadequate margins
(<5 mm or positive), while we noticed no local recur-
rences in the 15 patients who had pathologically
adequate margins (>5 mm) (Table 2).
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this treatment approach depend on attention to
technical details such as: wide resection with nega-
tive margins; marking of the tumor bed with metal
clips; adequate coverage of the tumor bed and
margins with the implant; loading of the implant
not earlier than the ® fth post-operative day; careful
dosimetry; and dose prescription tailored to the
clinical situation.
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